Biotechnology company OSE Immunotherapeutics (Euronext Paris:OSE) announced on Tuesday the launch of the Artemia trial to evaluate its cancer vaccine, Tedopi, in second-line treatment for metastatic non-small cell lung cancer (NSCLC).

The trial is being conducted in multiple countries and regions, including the United States, Canada, Europe and the United Kingdom.

Tedopi is a neoepitope-based vaccine designed to stimulate the immune system to target cancer cells. The Artemia trial will compare Tedopi to standard of care in HLA-A2 positive patients with NSCLC who have progressed after treatment with immune checkpoint inhibitors. The primary endpoint of the trial is overall survival.

OSE believes that Tedopi has the potential to address a significant unmet medical need for patients with advanced NSCLC.

The study is intended to support the registration of Tedopi, in parallel with the companion diagnostic for HLA-A2 positive patients.

NSCLC accounts for 85% of all lung cancers and the HLA-A2 phenotype represents about 45% of the population.